Home/Filings/4/0001048477-25-000017
4//SEC Filing

Guyer Charles Greg 4

Accession 0001048477-25-000017

CIK 0001048477other

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 7:17 PM ET

Size

9.0 KB

Accession

0001048477-25-000017

Insider Transaction Report

Form 4
Period: 2025-02-25
Guyer Charles Greg
EVP, Chief Technical Officer
Transactions
  • Award

    Common Stock

    2025-02-25+11,04079,949 total
  • Award

    Common Stock

    2025-02-25+9,66089,609 total
  • Award

    Common Stock

    2025-02-25+9,36798,976 total
Footnotes (5)
  • [F1]Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
  • [F2]Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
  • [F3]Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2025, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
  • [F4]Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
  • [F5]Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2022 through 2024 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Issuer

BIOMARIN PHARMACEUTICAL INC

CIK 0001048477

Entity typeother

Related Parties

1
  • filerCIK 0001811096

Filing Metadata

Form type
4
Filed
Feb 26, 7:00 PM ET
Accepted
Feb 27, 7:17 PM ET
Size
9.0 KB